CLS 002 - Comera Life Sciences
Alternative Names: CLS-002 - Comera Life SciencesLatest Information Update: 05 Apr 2023
Price :
$50 *
At a glance
- Originator Comera Life Sciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2023 Comera Life Sciences receives Notices of Allowance covering expansion of claims and exclusive rights pertaining to certain excipients in its proprietary SQore™ platform, in USA and Japan
- 03 Apr 2023 Comera Life Sciences has patent protection covering expansion of claims and exclusive rights pertaining to certain excipients in its proprietary SQore™ platform, in South Korea
- 30 Jan 2023 Comera Life Sciences announces intention to file an IND application for Cancer in 2024